MESO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mesoblast Ltd (MESO) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are positive developments in the company's Ryoncil product and an analyst upgrade, the technical indicators, options sentiment, and lack of significant trading signals suggest a neutral to slightly bearish short-term outlook. Given the investor's preference for long-term investments, it is advisable to hold off on purchasing until clearer positive trends emerge.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 43.427, and moving averages are converging, showing no strong directional trend. The stock is trading below its pivot level of 17.002, with key support at 15.921 and resistance at 18.083.
Ryoncil demonstrates high survival rates in SR-aGvHD, with plans for a pivotal trial for adult treatment. Jefferies upgraded the stock to Buy with a price target increase to A$3.30.
Technical indicators are bearish or neutral, and the stock trend analysis predicts a potential short-term decline. No significant hedge fund or insider trading activity has been observed.
Financial data is unavailable for the latest quarter, making it difficult to assess growth trends.
Jefferies upgraded the stock to Buy from Hold, raising the price target to A$3.30 from A$3, citing positive developments in Ryoncil and updated forecasts for FY26.
